the hanover insurance group inc. - THG
THG
Close Chg Chg %
170.47 1.80 1.06%
Closed Market
172.27
+1.80 (1.06%)
Volume: 261.54K
Last Updated:
Mar 26, 2026, 3:59 PM EDT
Company Overview: the hanover insurance group inc. - THG
THG Key Data
| Open $170.16 | Day Range 170.16 - 172.62 |
| 52 Week Range 147.76 - 188.18 | Market Cap $5.99B |
| Shares Outstanding 35.15M | Public Float 34.79M |
| Beta 0.32 | Rev. Per Employee N/A |
| P/E Ratio 9.39 | EPS $18.52 |
| Yield 214.08% | Dividend $0.95 |
| EX-DIVIDEND DATE Mar 13, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 304.01K |
THG Performance
| 1 Week | 2.04% | ||
| 1 Month | -4.62% | ||
| 3 Months | -6.47% | ||
| 1 Year | -0.20% | ||
| 5 Years | 31.40% |
THG Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 200.571 | |
| Number of Ratings | 9 | Current Quarters Estimate | 4.317 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 17.125 | |
| Last Quarter’s Earnings | 5.79 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 19.09 | Next Fiscal Year Estimate | 18.057 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 8 | 8 |
| Mean Estimate | 4.32 | 3.55 | 17.12 | 18.06 |
| High Estimates | 4.58 | 3.98 | 17.30 | 19.00 |
| Low Estimate | 4.09 | 2.87 | 16.93 | 17.50 |
| Coefficient of Variance | 3.80 | 11.70 | 0.82 | 2.57 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 4 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for The Hanover Insurance Group Inc. - THG
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for The Hanover Insurance Group Inc. - THG
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 4, 2025 | Jeffrey Mark Farber Executive Vice President | 45,855 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 8,524,903.05 |
| Dec 4, 2025 | John Conner Roche President and CEO; Director | 123,715 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 22,999,855.65 |
| Dec 4, 2025 | Bryan J. Salvatore Executive Vice President | 25,678 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 4,773,796.98 |
| Dec 4, 2025 | Dennis F. Kerrigan Executive Vice President | 9,740 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 1,810,763.40 |
| Apr 2, 2025 | Richard William Lavey Executive Vice President | 39,079 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,278 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.03 per share | 21,752,378.34 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,414 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,715 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $77.91 per share | 9,716,545.65 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,414 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175 per share | 21,772,450.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 9,207 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 8,906 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | Denise Tinger M. Lowsley Executive Vice President | 5,034 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | Willard T. Lee Executive Vice President | 5,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | David J. Lovely Executive Vice President | 2,254 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |